Unexpected Findings of Duchenne Muscular Dystrophy in Prenatal Screening of Chromosome Abnormality Based on Cell-Free Fetal DNA

Abstract

Objective

This study aims to assess the feasibility of detecting and diagnosing Duchenne muscular dystrophy (DMD) during prenatal screening for chromosome abnormalities using cell-free fetal DNA extracted from peripheral blood samples of pregnant women.

Study Design

Two pregnant women identified as high risk through noninvasive prenatal testing (NIPT) underwent amniocentesis to obtain fetal cells. Subsequent fetal chromosomal karyotyping was conducted, and genomic DNA from fetal cells was extracted for copy number variation sequencing (CNV-Seq) analysis, complemented by multiplex ligation-dependent probe amplification (MLPA) to detect deletions or duplications within the DMD gene.

Results

NIPT results for the two samples indicated potential abnormalities involving chromosomes 21 and 18. However, karyotype analysis of the fetuses revealed no abnormalities. CNV-Seq identified deletions of 0.28 and 0.18 Mb within chromosome Xp21.1, encompassing the DMD gene, in each fetus. In family 1, MLPA results indicated a maternal heterozygous deletion spanning exons 12 to 41 in the DMD gene, while the fetus exhibited deletions in exons 12 to 41. In family 2, MLPA results confirmed normal DMD gene status in the pregnant woman's peripheral blood genomic DNA but revealed a fetal deletion spanning exons 48 to 52. Both fetuses were diagnosed with DMD and subsequently underwent termination.

Conclusion

Abnormalities identified through NIPT necessitate further invasive prenatal diagnostic procedures. For cases involving chromosomal microdeletions or microduplications, a combination of karyotyping and CNV-Seq testing is essential for comprehensive diagnosis. NIPT followed by CNV-Seq may offer insights into large exon deletions within the DMD gene in specific instances.

Key Points

• NIPT results can offer valuable insights into the deletion and duplication of DMD gene for the fetus.

• It's crucial to notice unexpected findings in NIPT.

• A combination of karyotyping and CNV-Seq testing is essential for comprehensive diagnosis.

Keywords

noninvasive prenatal testing - cell-free fetal DNA - copy number variation sequencing - Duchenne muscular dystrophy - prenatal diagnosis

• References

• 1 Dungan JS, Klugman S, Darilek S. et al; ACMG Board of Directors. Electronic address: [e-mail]. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2023; 25 (02) 100336
• 2 Zaninović L, Bašković M, Ježek D, Katušić Bojanac A. Validity and utility of non-invasive prenatal testing for copy number variations and microdeletions: a systematic review. J Clin Med 2022; 11 (12) 3350
• 3 Turriff A, Miner SA, Annunziata CM, Bianchi DW. Patients' perspectives on prenatal screening results that suggest maternal cancer: a qualitative analysis. Prenat Diagn 2023; 43 (09) 1101-1109
• 4 Hu T, Wang J, Zhu Q. et al. Clinical experience of noninvasive prenatal testing for rare chromosome abnormalities in singleton pregnancies. Front Genet 2022; 13: 955694
• 5 Brison N, Storms J, Villela D. et al. Maternal copy-number variations in the DMD gene as secondary findings in noninvasive prenatal screening. Genet Med 2019; 21 (12) 2774-2780
• 6 Zhao JH, Dai P, Zhu RN, Shi PL, Meng JJ, Kong XD. [Confirmation and analysis of 2 398 positive results of cell-free fetal DNA]. Zhonghua Fu Chan Ke Za Zhi 2020; 55 (10) 679-684
• 7 Roberts TC, Wood MJA, Davies KE. Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov 2023; 22 (11) 917-934
• 8 Li L, Xia J, Jiao Z. et al. Unexpected findings of CNV-seq: analysis of partial DMD gene duplications in non-pathogenic fetal lineages and genetic counseling. Zhonghua Fu Chan Ke Za Zhi 2021; 56 (01) 64-68
• 9 Chiu RWK, Chan KCA, Gao Y. et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A 2008; 105 (51) 20458-20463
• 10 Zhong LPW, Chiu RWK. The next frontier in noninvasive prenatal diagnostics: cell-free fetal DNA analysis for monogenic disease assessment. Annu Rev Genomics Hum Genet 2022; 23: 413-425
• 11 Chen M, Chen C, Huang X. et al. Noninvasive prenatal diagnosis for Duchenne muscular dystrophy based on the direct haplotype phasing. Prenat Diagn 2020; 40 (08) 918-924
• 12 Zhao G, Wang X, Liu L, Dai P, Kong X. Noninvasive prenatal diagnosis of Duchenne muscular dystrophy in five Chinese families based on relative mutation dosage approach. BMC Med Genomics 2021; 14 (01) 275
• 13 Xu Y, Li X, Ge HJ. et al. Haplotype-based approach for noninvasive prenatal tests of Duchenne muscular dystrophy using cell-free fetal DNA in maternal plasma. Genet Med 2015; 17 (11) 889-896
• 14 Jang SS, Lim BC, Yoo SK. et al. Targeted linked-read sequencing for direct haplotype phasing of maternal DMD alleles: a practical and reliable method for noninvasive prenatal diagnosis. Sci Rep 2018; 8 (01) 8678
• 15 Hua C, Liu L, Kong X. Prenatal diagnosis of 1408 foetuses at risk of DMD/BMD by MLPA and Sanger sequencing combined with STR linkage analysis. BMC Med Genomics 2023; 16 (01) 310
• 16 Chitty LS. Non-invasive prenatal testing 10 years on. Prenat Diagn 2021; 41 (10) 1187-1189
• 17 Linthorst J, Baksi MMM, Welkers MRA, Sistermans EA. The cell-free DNA virome of 108,349 Dutch pregnant women. Prenat Diagn 2023; 43 (04) 448-456